Matches in SemOpenAlex for { <https://semopenalex.org/work/W2777961796> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2777961796 abstract "AbstractIn patients with HER2-negative metastatic breast cancer who are not candidates for endocrine therapy, several regimens are approved, but there is no consensus on which should be preferred. The impressive gains in progression-free survival achieved by combining two cytotoxic drugs or chemotherapy plus bevacizumab have not consistently translated into overall survival benefits. Survival in this population depends on a wide range of biological and clinical factors, some of which remain unclear. International guidelines recommend that combination regimens should be limited to clinically aggressive situations. However, an evidence-based definition that could help guide treatment decisions and trial design has not been established for so-called ‘poor-prognosis’ or ‘aggressive’ tumors. In this article, we summarize the current literature regarding prognosis and treatment of patients with no endocrine options for HER2-negative metastatic breast cancer. The choice of optimal systemic therapy should be based on robust prognostic factors, the biologic characteristics of the tumor, and the type and severity of comorbidities. Furthermore, we suggest that combination regimens (chemotherapy doublets or bevacizumab-based regimens) may be considered appropriate options for patients with well-defined criteria representing poor-prognosis disease." @default.
- W2777961796 created "2018-01-05" @default.
- W2777961796 creator A5001910485 @default.
- W2777961796 creator A5010399021 @default.
- W2777961796 creator A5026988255 @default.
- W2777961796 creator A5027877389 @default.
- W2777961796 creator A5040158829 @default.
- W2777961796 creator A5051629490 @default.
- W2777961796 creator A5071971525 @default.
- W2777961796 creator A5090108117 @default.
- W2777961796 date "2017-12-15" @default.
- W2777961796 modified "2023-10-18" @default.
- W2777961796 title "Challenges in Prognosis, Systemic Therapy, and Survival in Patients with HER2-Negative Metastatic Breast Cancer candidates to systemic chemotherapy" @default.
- W2777961796 doi "https://doi.org/10.18103/mra.v5i12.1587" @default.
- W2777961796 hasPublicationYear "2017" @default.
- W2777961796 type Work @default.
- W2777961796 sameAs 2777961796 @default.
- W2777961796 citedByCount "0" @default.
- W2777961796 crossrefType "journal-article" @default.
- W2777961796 hasAuthorship W2777961796A5001910485 @default.
- W2777961796 hasAuthorship W2777961796A5010399021 @default.
- W2777961796 hasAuthorship W2777961796A5026988255 @default.
- W2777961796 hasAuthorship W2777961796A5027877389 @default.
- W2777961796 hasAuthorship W2777961796A5040158829 @default.
- W2777961796 hasAuthorship W2777961796A5051629490 @default.
- W2777961796 hasAuthorship W2777961796A5071971525 @default.
- W2777961796 hasAuthorship W2777961796A5090108117 @default.
- W2777961796 hasConcept C121608353 @default.
- W2777961796 hasConcept C126322002 @default.
- W2777961796 hasConcept C143998085 @default.
- W2777961796 hasConcept C177713679 @default.
- W2777961796 hasConcept C185926286 @default.
- W2777961796 hasConcept C2775930923 @default.
- W2777961796 hasConcept C2776694085 @default.
- W2777961796 hasConcept C2777802072 @default.
- W2777961796 hasConcept C2779134260 @default.
- W2777961796 hasConcept C2779786085 @default.
- W2777961796 hasConcept C2781230642 @default.
- W2777961796 hasConcept C2908647359 @default.
- W2777961796 hasConcept C530470458 @default.
- W2777961796 hasConcept C535046627 @default.
- W2777961796 hasConcept C71924100 @default.
- W2777961796 hasConcept C99454951 @default.
- W2777961796 hasConceptScore W2777961796C121608353 @default.
- W2777961796 hasConceptScore W2777961796C126322002 @default.
- W2777961796 hasConceptScore W2777961796C143998085 @default.
- W2777961796 hasConceptScore W2777961796C177713679 @default.
- W2777961796 hasConceptScore W2777961796C185926286 @default.
- W2777961796 hasConceptScore W2777961796C2775930923 @default.
- W2777961796 hasConceptScore W2777961796C2776694085 @default.
- W2777961796 hasConceptScore W2777961796C2777802072 @default.
- W2777961796 hasConceptScore W2777961796C2779134260 @default.
- W2777961796 hasConceptScore W2777961796C2779786085 @default.
- W2777961796 hasConceptScore W2777961796C2781230642 @default.
- W2777961796 hasConceptScore W2777961796C2908647359 @default.
- W2777961796 hasConceptScore W2777961796C530470458 @default.
- W2777961796 hasConceptScore W2777961796C535046627 @default.
- W2777961796 hasConceptScore W2777961796C71924100 @default.
- W2777961796 hasConceptScore W2777961796C99454951 @default.
- W2777961796 hasIssue "12" @default.
- W2777961796 hasLocation W27779617961 @default.
- W2777961796 hasOpenAccess W2777961796 @default.
- W2777961796 hasPrimaryLocation W27779617961 @default.
- W2777961796 hasRelatedWork W144521535 @default.
- W2777961796 hasRelatedWork W1542715224 @default.
- W2777961796 hasRelatedWork W1579601833 @default.
- W2777961796 hasRelatedWork W1861802171 @default.
- W2777961796 hasRelatedWork W1976558416 @default.
- W2777961796 hasRelatedWork W2010108545 @default.
- W2777961796 hasRelatedWork W2019546222 @default.
- W2777961796 hasRelatedWork W2022069192 @default.
- W2777961796 hasRelatedWork W2091951796 @default.
- W2777961796 hasRelatedWork W2109887943 @default.
- W2777961796 hasRelatedWork W2112666042 @default.
- W2777961796 hasRelatedWork W2118892955 @default.
- W2777961796 hasRelatedWork W2129948966 @default.
- W2777961796 hasRelatedWork W2143588465 @default.
- W2777961796 hasRelatedWork W2292909024 @default.
- W2777961796 hasRelatedWork W2472402392 @default.
- W2777961796 hasRelatedWork W2811390920 @default.
- W2777961796 hasRelatedWork W2894441287 @default.
- W2777961796 hasRelatedWork W2993622917 @default.
- W2777961796 hasRelatedWork W3095067634 @default.
- W2777961796 hasVolume "5" @default.
- W2777961796 isParatext "false" @default.
- W2777961796 isRetracted "false" @default.
- W2777961796 magId "2777961796" @default.
- W2777961796 workType "article" @default.